iCMLf Conversation: Treatment of CML patients after failure of 2 TKIs

Expert:
Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology, Jena University Hospital (Germany)
Program:
Choice of an alternative TKI
Intolerance after ≥ 2 lines of TKIs
Allogeneic HCT in CML in Europe: EDMT Report
What is the right dose? Salvage / frontline
Results from the BYOND study and the OPTIC trial
Asciminib - an investigational first in class STAMP inhibitor
Asciminib study results: phase 1 study / combination with IM, NIL, or DAS,
ASCEMBL study, phase 3b treatment optimization study
Other new drugs in development incl. ELVN-001, PF114, olverembatinib and vodobatinib
Conclusion: expanding arsenal to fight failure of TKIs